PolyPeptide Group AG

PolyPeptide Group AG

0AAJ · London Exchange

PolyPeptide Group AG (0AAJ) is a Biotechnology company in the Healthcare sector, listed on London Exchange. This page provides the complete earnings calendar, dividend schedule, and financial data for PolyPeptide Group AG in 2026. The next earnings report is expected on March 9, 2027.

Earnings calendar

Next earnings date

09 Mar 2027

In 201 days

EPS estimate

0.71

Revenue estimate

307.2M

Past earnings

13 Aug 2026
EPS actual
—
estimate 0.08
Revenue actual
270.2M (+8.5%)
estimate 249.0M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
12 Mar 2026
EPS actual
—
estimate 0.34
Revenue actual
261.1M (0.0%)
estimate 261.1M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
12 Aug 2025
EPS actual
-0.94 (-40.4%)
estimate -0.67
Revenue actual
196.8M (+7.6%)
estimate 182.9M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
Beat Miss usd

Latest earnings analysis

PolyPeptide Group AG beat consensus estimates on revenue in its latest earnings report, with revenue of USD 270.21 million exceeding estimates by 8.5%, while EPS was not disclosed relative to a USD 0.0799 estimate. In the prior quarter revenue met expectations, and EPS was not disclosed against a USD 0.3406 estimate.

Dividend calendar

No dividend history available.

EPS (Earnings Per Share)

Revenue

Company profile

PolyPeptide Group AG operate as a contract development and manufacturing company worldwide. It focuses on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development, and in generic products. It engages in manufacturing custom research grade peptides; and developing neoantigen peptide to support personalized cancer therapies. The company is also involved in manufacturing peptides for commercially approved peptide therapeutics. In addition, it manufactures peptide-based generics for human and veterinary markets; and cosmetic peptides. Further, the company offers regulatory affair support services. The company was founded in 1952 and is headquartered in Zug, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.

Sector
Healthcare
Industry
Biotechnology
Country
Switzerland
Exchange
London Exchange
CEO
Juan Jose Gonzalez
Employees
1,362
IPO date
12 Nov 2021
ISIN
CH1110760852
Website
polypeptide.com

Frequently asked questions

When does PolyPeptide Group AG (0AAJ) next report earnings?

PolyPeptide Group AG (0AAJ) is scheduled to report earnings on March 9, 2027.

What was PolyPeptide Group AG's most recent earnings date?

PolyPeptide Group AG (0AAJ) last reported earnings on August 13, 2026.

Where is PolyPeptide Group AG stock listed?

PolyPeptide Group AG (0AAJ) is listed on London Exchange.